FDA Requires New Vision Loss Warnings for Ozempic, Wegovy and Other GLP-1s Over NAION Risk
Report from the mass tort press
Headline as published by AboutLawsuits.com on Nov 9, 2026; collected by the wire Nov 9, 2026, 5:01 PM ET.
Coverage
Named in this story
- AgencyU.S. Food and Drug AdministrationMatched on
FDA
- MDLMDL 3163 · GLP-1 Vision Loss (NAION)Matched on
NAION
Topics
- Mass torts and MDLsMatched on
NAION
- Drugs and medical devicesMatched on
side effects
Explore the named firms, organizations and MDL dockets above. Sources and method
MDL No. 3163
GLP-1 Vision Loss (NAION)
IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
- Transferee judge
- Karen S. Marston
- Court
- Eastern District of Pennsylvania
- Actions pending
- 247
Per the JPML pending-dockets report of October 1, 2026.